---
created: 2025-04-13
updated: 2025-04-13T10:51
id: `[sp{CC<c
specialty: cardio
specialty_id: 171
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - source/ak-step1-v11::
  - theme/firstaid::07-cardiovascular::05-pharm::04-hydralazine
  - source/ak-step1-v11::
  - source/ome-banner::clinical::01-cardiology::08-hypertension
  - source/ak-step1-v11::
  - theme/physeo::09-pharm::10-cardiac::03-hydralazine
  - source/ak-step1-v11::
  - theme/pixorize::03-pharm::06-cardio::hydralazine
  - source/ak-step1-v11::
  - theme/sketchypharm::02-cardio-&-renal::03-antihypertensives::02-primary-hypertension-&-hypertensive-emergency
  - source/ak-step1-v11::^other::^highyield::1-highyield
  - source/ak-step1-v11::^systems::cardio::pharmacology"
type: flashcard
---

# Question
Hydralazine is often co-administered with a(n) **Î²-blocker** to minimize the reflexive **sympathetic** activation and tachycardia

---

# Answer
